search
Back to results

Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals

Primary Purpose

Chronic Idiopathic Constipation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
vibrating capsule
sham non-vibrating capsule
Sponsored by
Vibrant Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Idiopathic Constipation focused on measuring constipation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients aged 18 years and older.
  2. Patients with chronic idiopathic constipation according to Rome III criteria and who have not experienced relief of their symptoms from available therapies (osmotic and stimulant laxatives which was used for at least one month at recommended dose).
  3. Patients with more than 1 bowel movement/2 weeks and < 3 bowel movement/week.
  4. Colonoscopy performed in the past 10 years prior to study participation, unless the patients are <50 years old and without alarming signs and symptoms
  5. Patient signed ICF
  6. For women with childbearing potential, adequate contraception

Exclusion Criteria:

  1. History of complicated/obstructive diverticular disease
  2. History of intestinal or colonic obstruction.
  3. History of significant GI disorder.
  4. Use of following medication: Medication that may affect the bowel mobility, Prokinetics, Anti-Depressants, medications for treatment of Parkinson disease, Opiates, Calcium-channel Blockers, Aluminium/Magnesium Hydroxids
  5. Clinical evidence of significant respiratory, CVS, renal, hepatic, biliary, endocrine, psychiatric, neurologic, or presence of abdominal pacemakers.
  6. Presence of pacemaker.
  7. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.
  8. Diagnosis of mega-rectum or colon, a history of intestinal obstruction, congenital anorectal malformation, clinically significant rectocele, or any evidence of intestinal structural abnormality, including GI resection that affects bowel transit, or any evidence of intestinal carcinoma or inflammatory bowel disease of alarm symptoms such as weight loss, rectal bleeding, or anaemia.
  9. History of Zenker's diverticulum, dysphagia or a known esophageal stricture 10. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)

11. Participation in another clinical study in the last 4 months prior to screening.

12. Any other condition which in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the clinical study.

13. Women who are pregnant or lactating.

-

Sites / Locations

  • Borland-Groover Clinic
  • Georgia Regents University
  • MGG Group Co., Inc., Chevy Chase Clinical Research
  • Mgh Boston
  • University of Michigan Hospital
  • Mayo Clinic Rochester
  • Albuquerque Neuroscience
  • NYU Langone Medical Center
  • Temple University School of Medicine
  • CTRS LLC
  • Huoston Methodist Hosptial
  • Bat-Yamon
  • Degani center Clalit MC
  • Expert clinic Clalit MC
  • Talpiot clinic Clalit MC
  • Zvoulon MC Clalit MC
  • 100 Tower
  • Souraski Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Vibrating capsule

sham non-vibrating capsule

Arm Description

patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].

patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].

Outcomes

Primary Outcome Measures

Frequency of bowel movements
change from baseline in the weekly Spontaneous Bowel Movement (SBM) rate during treatment period. Success will be defined as increase by at least 1 SBM/week. The primary analysis will be a comparative analysis of success rates between the study groups

Secondary Outcome Measures

Full Information

First Posted
January 7, 2014
Last Updated
November 5, 2017
Sponsor
Vibrant Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02030756
Brief Title
Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals
Official Title
Assessment of the Performance, Efficacy and Safety of Vibrating Capsule Medical Device in Aiding Reliving Constipated Individuals.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vibrant Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a study intended to evaluate the efficacy and safety of the vibrating capsule versus sham non-vibrating capsule on spontaneous bowel movement, in aiding reliving Constipated Individuals

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Idiopathic Constipation
Keywords
constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vibrating capsule
Arm Type
Active Comparator
Arm Description
patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
Arm Title
sham non-vibrating capsule
Arm Type
Sham Comparator
Arm Description
patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
Intervention Type
Device
Intervention Name(s)
vibrating capsule
Intervention Description
patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
Intervention Type
Device
Intervention Name(s)
sham non-vibrating capsule
Intervention Description
patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
Primary Outcome Measure Information:
Title
Frequency of bowel movements
Description
change from baseline in the weekly Spontaneous Bowel Movement (SBM) rate during treatment period. Success will be defined as increase by at least 1 SBM/week. The primary analysis will be a comparative analysis of success rates between the study groups
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18 years and older. Patients with chronic idiopathic constipation according to Rome III criteria and who have not experienced relief of their symptoms from available therapies (osmotic and stimulant laxatives which was used for at least one month at recommended dose). Patients with more than 1 bowel movement/2 weeks and < 3 bowel movement/week. Colonoscopy performed in the past 10 years prior to study participation, unless the patients are <50 years old and without alarming signs and symptoms Patient signed ICF For women with childbearing potential, adequate contraception Exclusion Criteria: History of complicated/obstructive diverticular disease History of intestinal or colonic obstruction. History of significant GI disorder. Use of following medication: Medication that may affect the bowel mobility, Prokinetics, Anti-Depressants, medications for treatment of Parkinson disease, Opiates, Calcium-channel Blockers, Aluminium/Magnesium Hydroxids Clinical evidence of significant respiratory, CVS, renal, hepatic, biliary, endocrine, psychiatric, neurologic, or presence of abdominal pacemakers. Presence of pacemaker. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating. Diagnosis of mega-rectum or colon, a history of intestinal obstruction, congenital anorectal malformation, clinically significant rectocele, or any evidence of intestinal structural abnormality, including GI resection that affects bowel transit, or any evidence of intestinal carcinoma or inflammatory bowel disease of alarm symptoms such as weight loss, rectal bleeding, or anaemia. History of Zenker's diverticulum, dysphagia or a known esophageal stricture 10. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) 11. Participation in another clinical study in the last 4 months prior to screening. 12. Any other condition which in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the clinical study. 13. Women who are pregnant or lactating. -
Facility Information:
Facility Name
Borland-Groover Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Georgia Regents University
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Facility Name
MGG Group Co., Inc., Chevy Chase Clinical Research
City
Chevy Chase
State/Province
Maryland
ZIP/Postal Code
20815
Country
United States
Facility Name
Mgh Boston
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
University of Michigan Hospital
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Mayo Clinic Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Albuquerque Neuroscience
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87109
Country
United States
Facility Name
NYU Langone Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Temple University School of Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
CTRS LLC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15206
Country
United States
Facility Name
Huoston Methodist Hosptial
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Bat-Yamon
City
Bat Yam
Country
Israel
Facility Name
Degani center Clalit MC
City
Hadera
Country
Israel
Facility Name
Expert clinic Clalit MC
City
Herzliya
Country
Israel
Facility Name
Talpiot clinic Clalit MC
City
Jerusalem
Country
Israel
Facility Name
Zvoulon MC Clalit MC
City
Kiryat Bialik
Country
Israel
Facility Name
100 Tower
City
Tel Aviv
Country
Israel
Facility Name
Souraski Medical Center
City
Tel Aviv
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals

We'll reach out to this number within 24 hrs